mRNA treatment for EBV-related diseases
Part of Cancer, Infections clinical trials.
This trial tests a new mRNA-based treatment for people with Epstein-Barr virus (EBV) related diseases, such as certain cancers or EBV illness after a transplant. The goal is to see if the treatment can help your immune system fight the virus and the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a disease caused by the Epstein-Barr virus (EBV), such as nasopharyngeal cancer, stomach cancer, lymphoma, or EBV illness after a stem cell transplant.
- You are able to do your daily activities with little help (ECOG score 0-2).
- Your major organs (like liver, kidneys, heart) are working well enough.
- You have not had chemotherapy, radiation, or other cancer treatments in the last 4 weeks (or 2 weeks for palliative radiation).
- You are not taking high-dose steroids or other strong immune-suppressing drugs right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an mRNA vaccine to treat advanced cancers linked to the Epstein-Barr virus, such as nasopharyngeal cancer, NK/T-cell lymphoma, and stomach cancer. The vaccine teaches your immune system to fight the virus and the cancer.
This trial tests a new injection called WGc-043 for people with advanced solid tumors that are linked to the Epstein-Barr virus. It aims to see if the treatment is safe and may help shrink tumors.
This trial tests an experimental mRNA vaccine designed to target cancer cells infected with the Epstein-Barr virus (EBV). It is for people with certain types of lymphoma that have come back or not responded to standard treatments. The goal is to see if the vaccine can help the immune system fight the cancer.
This trial tests an mRNA vaccine that may help prevent Epstein-Barr virus (EBV) infections and related diseases after a stem cell transplant. It is for people who have received or will receive a donor stem cell transplant.
This trial tests an experimental mRNA vaccine (mRNA-1189) to see if it can prevent Epstein-Barr virus (EBV) infection. It is for healthy adults 18 to 30 years old.
This trial tests a new immune therapy for people with Epstein-Barr virus (EBV)-related lymphoproliferative diseases, including chronic active EBV and conditions that can occur after an organ or stem cell transplant. It aims to see if the therapy can safely control the disease.
Hear when a new EBV-associated Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.